Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2021

Mavragani CP, Kirou KA, Nezos A, Seshan S, Wild T, Wahl SM, et al. Expression of APOBEC family members as regulators of endogenous retroelements and malignant transformation in systemic autoimmunity. Clin Immunol. 2021;223:108649.

Gaffney C, Liu D, Cooley V, Ma X, Angulo C, Robinson B, et al. Tumor size and genomic risk in localized prostate cancer. Urol Oncol. 2021;39(7):434.e17-434.e22.

Grbesa I, Augello MA, Liu D, McNally DR, Gaffney CD, Huang D, et al. Reshaping of the androgen-driven chromatin landscape in normal prostate cells by early cancer drivers and effect on therapeutic sensitivity. Cell Rep. 2021;36(10):109625.

Gjyrezi A, Galletti G, Zhang J, Worroll D, Sigouros M, Kim S, et al. Androgen receptor variant shows heterogeneous expression in prostate cancer according to differentiation stage. Commun Biol. 2021;4(1):785.

Barbhaiya M, Zuily S, Ahmadzadeh Y, Amigo M-, Avcin T, Bertolaccini ML, et al. Development of a New International Antiphospholipid Syndrome Classification Criteria Phase I/II Report: Generation and Reduction of Candidate Criteria. Arthritis Care Res (Hoboken). 2021;73(10):1490-1501.

Zoughbi WA, Fox J, Beg S, Papp E, Hissong E, Ohara K, et al. Validation of a Circulating Tumor DNA-Based Next-Generation Sequencing Assay in a Cohort of Patients with Solid tumors: A Proposed Solution for Decentralized Plasma Testing. Oncologist. 2021.

Craney A, Petrik D, Suhku A, Qiu Y, Racine-Brzostek S, Rennert H, et al. Performance Evaluation of the MatMaCorp COVID-19 2SF Assay for the Detection of SARS-CoV-2 from Nasopharyngeal Swabs. Microbiol Spectr. 2021;9(1):e0008321.

Cejas P, Xie Y, Font-Tello A, Lim K, Syamala S, Qiu X, et al. Subtype heterogeneity and epigenetic convergence in neuroendocrine prostate cancer. Nat Commun. 2021;12(1):5775.

Ferraro GB, Ali A, Luengo A, Kodack DP, Deik A, Abbott KL, et al. Author Correction: Fatty acid synthesis is required for breast cancer brain metastasis. Nat Cancer. 2021;2(11):1243.

Morel KL, Sheahan AV, Burkhart DL, Baca SC, Boufaied N, Liu Y, et al. EZH2 inhibition activates a dsRNA-STING-interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer. Nat Cancer. 2021;2(4):444-456.